http://www.proactiveinvestors.co.uk Proactiveinvestors RSS feed en Thu, 14 Dec 2017 13:03:14 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - OptiBiotix inks US manufacturing and supply deal for its SlimBiome appetite suppressant ]]> http://www.proactiveinvestors.co.uk/companies/news/188632/optibiotix-inks-us-manufacturing-and-supply-deal-for-its-slimbiome-appetite-suppressant-188632.html Life sciences group OptiBiotix Health PLC (LON:OPTI) has signed a manufacturing and supply agreement with US-based speciality ingredients manufacturer Cereal Ingredients Inc (CII).

The deal grants CII a licence to manufacture and supply Opti’s SlimBiome appetite suppressant in its range of cereal and protein-based particulates in the USA.

READ: Optibiotix Health's Slimbiome wins award at major food event

In return, AIM-quoted OptiBiotix will get a 50% cut of the profits, with an agreed cost of manufacture and minimum price already in place.

By partnering with CII, Opti said SlimBiome would now find its way into food products such as cookies, cakes, crackers and cereal bars, as well as cereals.

Under the terms of the agreement, CII will “use their best endeavours” to promote SlimBiome across the USA and bring it to the attention of as many buyers as possible.

Opti called Tuesday’s tie-up a “strategic step” in its bid to access the global healthy ingredients markets, which is estimated will be worth US$101bn by 2022.

“We chose Cereal Ingredients due to their industry reputation and world leading expertise in incorporating functional ingredients like SlimBiome into extruded cereal and protein based particulates bringing added value and differentiation to the cereal, snacks and sports nutrition markets,” said Opti chief executive Stephen O’Hara.

READ: Coffee that loses you weight among products being developed by Optibiotix

“We were particularly impressed by the investment in development work, marketing and customer engagement carried out by CII during negotiations which have given both companies a high level of confidence in the scale of the opportunity open to us.

“We believe working with CII, and similar partners around the world, provides the best opportunity of fully exploiting the functional benefits of SlimBiome to improve the health of customers around the world.”

]]>
Tue, 12 Dec 2017 07:36:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188632/optibiotix-inks-us-manufacturing-and-supply-deal-for-its-slimbiome-appetite-suppressant-188632.html
<![CDATA[RNS press release - Manufacturing, supply & profit sharing agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171212070002_13461541/ Tue, 12 Dec 2017 07:00:02 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171212070002_13461541/ <![CDATA[News - Lower blood pressure guidance will highlight Optibiotix's cholesterol reducer believes chief ]]> http://www.proactiveinvestors.co.uk/companies/news/188464/lower-blood-pressure-guidance-will-highlight-optibiotix-s-cholesterol-reducer-believes-chief-188464.html A reduction in levels of blood pressure required for a diagnosis of hypertension will highlight the advantages of non-prescription alternatives, believes Stephen O’Hara at Optibiotix Health PLC (LON:OPTI) .

Last month the American Heart Association changed its classification of high blood pressure to a reading of 130/80 from 140/90, a move that instantly put half of the US population in the unhealthy category.

Reports in the UK have suggested that health watchdog NICE (National Institute for Health and Care Excellence) is also considering lower guidance, action that would classify millions more Britons as medically unfit.

“There is no natural cut-off point above which ‘hypertension’ definitively exists and below which it does not” NICE said.

High blood pressure, or hypertension, hardens the arteries and increases the risk of heart disease, diabetes and strokes

Heart problems account for a quarter of all deaths in the UK.

O’Hara, Optiobiotix’s chief executive, believes a new class of probiotics that modulate the human microbiome can help people with high blood pressure to manage the condition.

Statins are the standard treatment to lower cholesterol but O'Hara says LPldl is a viable non-prescription alternative.

“We believe that our microbiome modulating probiotic, LPLDL, is not only a cutting-edge scientific development, but a safe and natural way for people to reduce their blood pressure, and to effectively manage their long-term cardiovascular risk,” he said in an article in Nutraceutical Review.

A study at Reading University showed it was a safe and reduced LDL cholesterol by up to 13.9%, and blood pressure by 5.1%.

LPldl works by affecting the metabolism of bile acids in the intestine and was chosen after 4,000 microbial candidates were assessed using Optibiotix’s Optiscreen platform.

]]>
Thu, 07 Dec 2017 14:28:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188464/lower-blood-pressure-guidance-will-highlight-optibiotix-s-cholesterol-reducer-believes-chief-188464.html
<![CDATA[Media files - Cheers for the new Chairman at Optibiotix ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8493/cheers-for-the-new-chairman-at-optibiotix-8493.html Tue, 05 Dec 2017 15:55:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/8493/cheers-for-the-new-chairman-at-optibiotix-8493.html <![CDATA[News - OptiBiotix names food industry heavy hitter as its new chairman ]]> http://www.proactiveinvestors.co.uk/companies/news/188242/optibiotix-names-food-industry-heavy-hitter-as-its-new-chairman-188242.html Life sciences group OptiBiotix Health plc (LON:OPTI) is recruiting a food industry heavy hitter to the role of chairman.

Former Express Dairies and Arla Foods chief executive Neil Davidson will take over from Adam Reynolds next month.

Currently a non-executive with the supermarket giant Wm Morrison (LON:MRW), he has also been an independent director at the housebuilder Persimmon (LON:PSN).

It means the new boardroom hire brings with him significant FTSE 100 experience – although he also chaired AIM-quoted Produce Investments.

Personal interest in innovation 

OptiBiotix said Davidson “has a personal interest in the development and commercialisation of technology to improve health”. 

That would appear to make him the ideal fit with the Opti, a pioneer of the human microbiome found in the gut.

It is using its knowledge and discoveries to develop healthy sweeteners and natural alternatives to current drugs for cholesterol and diabetes.

Chief executive Stephen O’Hara said of the chairman-elect: “His network of contacts and wealth of experience on the board of some of the UK's largest public companies will help guide OptiBiotix as it builds a microbiome business in what is forecast to be one of the world's fastest growth areas.

“The board anticipates a future where microbiome products will be at the forefront of preventing, managing and treating many of today's chronic lifestyle disease and we hope under Neil's guidance OptiBiotix will continue to be one of the world's leaders in this exciting and emerging field.”

The shares rose 3% in morning trade to 69.37p, valuing the business at £52mln.

---adds share price---

]]>
Tue, 05 Dec 2017 07:29:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188242/optibiotix-names-food-industry-heavy-hitter-as-its-new-chairman-188242.html
<![CDATA[RNS press release - Proposed directorate changes ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171205070010_13453703/ Tue, 05 Dec 2017 07:00:10 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171205070010_13453703/ <![CDATA[News - OptiBiotix: Kellogg’s move highlights the need for healthy alternative to sugar. Does one of AIM’s innovators have the answer? ]]> http://www.proactiveinvestors.co.uk/companies/news/188205/optibiotix-kelloggs-move-highlights-the-need-for-healthy-alternative-to-sugar-does-one-of-aims-innovators-have-the-answer-188205.html Kellogg's said it is to cut the amount of sugar in its three top-sellers ­- Coco Pops, Rice Krispies and Rice Krispies Multi-Grain Shapes - by 20-40%. It’s also told the world last week will also stop selling Ricicles and end on-pack promotions aimed at children on Frosties.

The move comes amid pressure on food firms to cut sugar levels to combat obesity, which will be music to the ears of management of one of AIM’s most innovative companies: OptiBiotix Health plc (LON:OPTI).

It is developing natural sweet prebiotics that can be used to replace sugar in food and drinks.  These may be classified as dietary fibres, which from an industry and consumer perspective, creates the prospect of substituting high-calorie sugars with sweet, healthy fibres.

Growing interest in natural sweeteners

Chief executive Stephen O’Hara told Proactive: “With growing consumer interest in healthy lifestyles public interest and political concerns over traditional sugars and artificial sweeteners OptiBiotix is leading research in an area of growing industry interest.”

The company is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

With this in mind, it is developing compounds to tackle obesity, high cholesterol and diabetes.

SkinBioTherapeutics spun off 

After spinning off its SkinBio business as a separately listed entity earlier this year, the group is now focused on three development areas.

They are OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

The current year has been one of significant commercial progress, including product launches and sales agreements.

In November it inked a deal with an offshoot of Premier Foods that makes Birds Custard.

Knighton Foods will improve the formulation of Opti’s SlimBiome weight loss product so it tastes better and dissolves more easily. This will tap the product into the firm’s network of customers, which includes the major supermarket chains.

Tata too

Opti also has an alliance with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.

LPLDL is another of its innovations that is gaining market traction.

OptiBiotix struck a profit-sharing deal with Italian firm Sacco to manufacture and supply cholesterol-reducing compound and the first sales of the product were made to HLH BioPharma Vertriebs·   

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.

WATCH: OptiBiotix pair point to massive marketing opportunities 

Having created value from the SkinBio demerger recently, CEO O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

With the market for its innovations expanding by the day, this looks like a very smart idea. Or as Tony the Tiger, the smiling cartoon on the front of every Frosties box might say, ‘it’s Grrrrreat’. 

]]>
Mon, 04 Dec 2017 14:12:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/188205/optibiotix-kelloggs-move-highlights-the-need-for-healthy-alternative-to-sugar-does-one-of-aims-innovators-have-the-answer-188205.html
<![CDATA[News - OptiBiotix rejig will allow the life sciences group pay a dividend ]]> http://www.proactiveinvestors.co.uk/companies/news/187875/optibiotix-rejig-will-allow-the-life-sciences-group-pay-a-dividend-187875.html Life sciences group OptiBiotix Health plc (LON:OPTI) is seeking shareholder consent to re-organise its capital structure so it can make future dividend payments.

Rather than making regular cash pay-outs, the company wants to be able to sanction a “dividend in specie” that would allow it to distribute its holding in SkinBioTherapeutics PLC (LON:SBX).

READ: Coffee that loses you weight among products being developed by Optibiotix

After spinning off the business, which is focused on treatments that use and modify the microbiome that resides on the skin, OptiBiotix still holds 41.9% of the separately listed firm.

The mechanics

The nuts and bolts of what is essentially a procedural matter are as follows: a proposed capital reduction will lead to the cancellation of OptiBiotix’s share premium account.

This will then create distributable reserves that will allow it to pay dividends either in cash, or in specie “should circumstances in the future make it desirable to do so”.

WATCH: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

Distributing shares in SkinBioTherapeutics means OptiBiotix is not forced to sell stock in the market and then make a cash return.  

Greater flexibility 

“The ability to make dividend payments provides the flexibility to consider paying a 'dividend in specie' to the company's shareholders of shares it holds in SkinBioTherapeutics, should it be appropriate to do so,” said Opti’s chief executive Stephen O'Hara.

“This is part of our strategy of building value across OptiBiotix divisions and where possible releasing value back to shareholders."

The company is a specialist in the emerging area of life science that involves the gut microbiome and is developing functional foods and treatments that help lower cholesterol, aid weight loss and which could help prevent diabetes.

]]>
Tue, 28 Nov 2017 07:29:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/187875/optibiotix-rejig-will-allow-the-life-sciences-group-pay-a-dividend-187875.html
<![CDATA[RNS press release - Capital reorganisation ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171128070002_13445440/ Tue, 28 Nov 2017 07:00:02 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171128070002_13445440/ <![CDATA[News - Optibiotix Health's Slimbiome wins award at major food event ]]> http://www.proactiveinvestors.co.uk/companies/news/187713/optibiotix-health-s-slimbiome-wins-award-at-major-food-event-187713.html Optibiotix Health PLC ’s (LON:OPTI) weight loss additive SlimBiome has won the award for  'Best Functional Ingredient for Health and Well Being’ at the prestigious Food Matters event.

Stephen O’Hara, Optibiotix’s chief executive, said he was delighted, especially as it recognised the innovation and scientific credibility behind SlimBiome.

READ: Coffee that loses you weight among products being developed by Optibiotix

“This award reflects the growing scientific and consumer evidence base which show that the incorporation of SlimBiome into food products helps customers to manage their weight loss (typically 2-3lbs) by reducing food intake without food cravings.”  

Optibiotix has developed a number of pro-biotics products based on the science of the human microbiome, the bacteria in the gut.

OptiScreen is for lowering cholesterol. OptiBiotics is a natural sweet fibre to help with diabetes control while Slimbiome is the weight management product.

Slimbiome is designed to stop you feeling hungry and a step forward from diets that rely on will-power and calorie restriction, he said.

“This new approach to weight management contrasts with many existing products which lack strong scientific rationale and typically rely on customers’ self-control.”

“Hunger free dieting is now a consumer option,” he added.

READ: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

Optibiotix recently signed a revenue sharing deal with Premier Foods’ subsidiary Knighton’s to develop Slimbiome.

That followed an agreement with Tata Chemical for Slimbiome to be distributed in India.

“We are working with national and international partners to incorporate SlimBiome into a wide range of food products and bring next generation functional weight management products to help improve the health and well being of consumers around the world.”

]]>
Thu, 23 Nov 2017 13:00:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/187713/optibiotix-health-s-slimbiome-wins-award-at-major-food-event-187713.html
<![CDATA[RNS press release - Exercise of Warrant and Issue of Equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171117150632_13436125/ Fri, 17 Nov 2017 15:06:32 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171117150632_13436125/ <![CDATA[News - Coffee that loses you weight among products being developed by Optibiotix ]]> http://www.proactiveinvestors.co.uk/companies/news/187084/coffee-that-loses-you-weight-among-products-being-developed-by-optibiotix-187084.html How does an instant coffee that will lose you ten pounds of weight in three months sound?

Wishful thinking perhaps.

WATCH: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

Not according to the team at microbiome specialist Optibiotix PLC (LON:OPTI), who have just such a product going through the trial process.

Indeed, instant coffee is one of a whole range of products being developed to incorporate Slimbiome, a microbiome-based additive invented by Optibiotix that basically stops you feeling hungry.

And the results have been staggering, says nutritionist Max Tomlinson, founder of the Healthy Weight Loss Company, the business behind the GoFigure brand.

He admits a degree of scepticism over the claims for Slimbiome when Optibiotix first bought into his company in 2016  (it recently upped its stake to 64%), but not now.

“If you genuinely are a considerate dieter, you will not feel hungry,” he says.  

“It [Slimbiome] is a combination of great oils, proteins, carbohydrate.

“It’s a great food but you can’t have more than sachet.”  

And that is the point. 

READ: OptiBiotix licenses weight-loss technology to Premier Foods offshoot

No one knew five years ago what the microbiome was and how important it was, adds Tomlinson, but Slimbiome is a fantastic compound that slows food transit down and stabilises blood sugars.

It is fat that Slimbiome reduces, not just weight, he says.

Shakes, mueslis, bakery products, cereals and nutrition bars are all products that soon will contain a Slimbiome element, but that might be just the start, according to sales and marketing director Christina Wood.

Partnerships have already been established with a number of companies around the world with Premier Foods subsidiary Knighton’s in the UK the latest.

Industry starting to take notice

Knighton’s is also working with Optibiotix to develop Slimbiome further.

The two have just launched a revised version of the product that enhances its use, flavour and mouth feel to position it for the opportunities opening up in bakeries, snacking and the growing ‘shakes’ market.

GoFigure products already are stamped ‘contains Slimbiome’, but Wood wants the brand to become generic in the healthy dieting business.

“A functional ingredient that can be incorporated into a lot of mainstream products to help people maintain a healthy lifestyle,” is how she describes it.

Industry insiders have also started to take notice.

Slimbiome has been short-listed for best functional ingredient for health and wellbeing at the upcoming Food Matters Live gathering.

But if it works as well as Tomlinson and Wood say, it is likely this will just be the one of many such nominations.

]]>
Fri, 10 Nov 2017 12:36:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/187084/coffee-that-loses-you-weight-among-products-being-developed-by-optibiotix-187084.html
<![CDATA[News - Optibiotix and Knighton's to launch improved version of microbiome-based appetite suppressant Slimbiome ]]> http://www.proactiveinvestors.co.uk/companies/news/186926/optibiotix-and-knighton-s-to-launch-improved-version-of-microbiome-based-appetite-suppressant-slimbiome-186926.html Microbiome pioneer OptiBiotix Health PLC (LON:OPTI) will launch its revised formulation of hunger suppressant product SlimBiome, using a powder technology developed by new partner Knighton’s.

Knighton’s tehcnology will make SlimBiome easier to dissolve and enhances its ease of use, flavour and mouthfeel, said Optibiotix, and will open opportunities in bakeries, snacking, coffee shops and the growing ‘shakes’ market.

WATCH: Massive opportunities for OptiBiotix Health's new and improved SlimBiome

SlimBiome will be sold as an ingredient in white label format and will be highlighted in OptiBiotix's own brand the GoFigure range of shakes and bars.

AIM-listed Optibiotix wants to target the growing  'Health & Wellbeing' lifestyle trend and sees a huge possible range of applications with new flavours and applications such as muesli.

Knighton’s, part of Premier Foods, is one of a number partners that are using Slimbiome to develop products such as cookies, tortillas, breakfast cereals, food toppings, yoghurts and cereal bars.

Eventually, the plan is to ‘white label’ Slimbiome to large retailers, and branded consumer products manufacturers as well as food manufacturers.

READ: OptiBiotix licenses weight-loss technology to Premier Foods offshoot

Slimbiome has been developed from Optibiotix’s work on the human microbiome, the bacteria that inhabits the gut and skin and that is increasingly being recognised as playing a critical part in the way the human body processes food.

 Stephen O'Hara, Optibiotix chief executive, said: “We anticipate SlimBiome being the first in a family of products to include: ImmunBiome, WellBiome, OptiBiome and CardioBiome, developed using our advanced microbiome modulating technology platforms.”

 

 

]]>
Wed, 08 Nov 2017 07:43:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/186926/optibiotix-and-knighton-s-to-launch-improved-version-of-microbiome-based-appetite-suppressant-slimbiome-186926.html
<![CDATA[RNS press release - SlimBiome® commercial & product development update ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171108070003_13423828/ Wed, 08 Nov 2017 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171108070003_13423828/ <![CDATA[Media files - Massive opportunities for OptiBiotix Health's new and improved SlimBiome ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8331/massive-opportunities-for-optibiotix-health-s-new-and-improved-slimbiome-8331.html Mon, 06 Nov 2017 12:52:00 +0000 http://www.proactiveinvestors.co.uk/companies/stocktube/8331/massive-opportunities-for-optibiotix-health-s-new-and-improved-slimbiome-8331.html <![CDATA[News - OptiBiotix licenses weight-loss technology to Premier Foods offshoot ]]> http://www.proactiveinvestors.co.uk/companies/news/186548/optibiotix-licenses-weight-loss-technology-to-premier-foods-offshoot-186548.html OptiBiotix Health plc (LON:OPTI) has signed a profit sharing agreement with a division of Premier Foods, which will manufacture and distribute the breakthrough weight-loss product, SlimBiome.

The deal is with Knighton Foods, a supplier of powdered products to supermarkets and High Street coffee houses.

The synergy lies with Knighton's advanced powder technology.

WATCH: Microbiome pioneer looks to ramp up revenues READ: In-depth look at OptiBiotix

This, OptiBiotix said, was the key to developing an improved version of its product which is more easily soluble than the original and presents better.

Crucially for the end consumer, the flavour has been “greatly improved” along with ‘mouthfeel’.

“We chose Knighton due to their world leading expertise in adding value and differentiation to speciality powdered ingredients like SlimBiome,” said Stephen O’Hara, chief executive of the AIM-listed company.

“Their development work greatly improved SlimBiome's solubility, taste and mouthfeel whilst reducing the overall cost of manufacture.”

Exclusive UK deal 

Knighton will have the exclusive licence to manufacture and supply SlimBiome in the UK.

In return OptiBiotix will receive 50% of the profit. Also contained in the deal terms is an agreed cost of manufacture and minimum sales price per kilogramme.

“We believe working with Knighton, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and the growing interest we are seeing in SlimBiome from partners worldwide," said O’Hara.

Positive endorsement

The broker finnCap said the Knight on deal was a positive endorsement of SlimBiome.

“Whilst the company is reluctant to provide sales forecast until it has developed a trading pattern, investors should note the positive momentum that is being displayed by OptiBiotix across all technology platforms,” said analyst Alex Pye.

The shares, up a fifth in the year to date, added a further 3% Wednesday to trade at 73p each. That values the business at just shy of £57mln.

Microbiome pioneer

OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

Using its know-how it is developing compounds to tackle obesity (SlimBiome), high cholesterol and diabetes.

Knighton is just one of a series of deals Opti has inked of late. It has one with Tata Chemicals to develop weight management products for the Indian market.

It struck a profit-sharing deal with Italian firm Sacco to manufacture and supply its cholesterol-reducing compound LPLDL and the first sales of the product were made to HLH BioPharma Vertriebs·   

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.  

]]>
Wed, 01 Nov 2017 07:35:00 +0000 http://www.proactiveinvestors.co.uk/companies/news/186548/optibiotix-licenses-weight-loss-technology-to-premier-foods-offshoot-186548.html
<![CDATA[RNS press release - Manufacturing, supply & profit sharing agreement ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171101070003_13415651/ Wed, 01 Nov 2017 07:00:03 +0000 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171101070003_13415651/ <![CDATA[Media files - Optibiotix Health focused on marketing and ramping up revenues ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8299/optibiotix-health-focused-on-marketing-and-ramping-up-revenues-8299.html Fri, 27 Oct 2017 14:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/8299/optibiotix-health-focused-on-marketing-and-ramping-up-revenues-8299.html <![CDATA[News - Leading scientist to present latest OptiBiotix research at industry conference in San Diego ]]> http://www.proactiveinvestors.co.uk/companies/news/186243/leading-scientist-to-present-latest-optibiotix-research-at-industry-conference-in-san-diego-186243.html One of the world’s leading microbiome scientists is to present OptiBiotix Health plc’s (LON:OPTI) latest research at a large industry conference in San Diego next week.

Professor Bob Rastall will speak at the Microbiome R&D and Business Collaboration on November 2-3.

Opti’s technology can boost health benefits of probiotics

The presentation will cover the work carried out by Opti alongside the University of Reading on OptiBiotics – combinations of a probiotic and a targeted prebiotic that enhance the health benefits of typical probiotic products.

READ: Optibiotix ties with Spain's Galenicum to extend reach of microbiome-based cholesterol reducer

Opti said the new product concept is a “more rational and scientific approach” to develop optimised synbiotics – when a product contains a prebiotic and probiotic – that boost a product’s health benefits in a market estimated to be worth almost US$50bn by 2020.

Rastall will also present research on how OptiBiotix has been able to enhance the cholesterol-reducing effect of its LPLDL strain.

Presentations grow credibility of research

“These presentations at major international conferences are important steps in establishing the scientific maturity and credibility of our technologies,” said Opti chief executive Stephen O’Hara.

“We are particularly pleased that Professor Bob Rastall, one of the world’s leading scientists in this field is presenting the research which was undertaken under his leadership at the University of Reading.”

He added: “The last 12 months has seen an increase in the number of presentations and publications on OptiBiotix's research reflecting the growing interest and maturity of our science.

“These presentations and publications help build awareness of OptiBiotix's technology and products in international markets and provide the scientific evidence base to support commercialisation of our next generation prebiotics, probiotics, and OptiBiotic products.”

]]>
Thu, 26 Oct 2017 07:38:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/186243/leading-scientist-to-present-latest-optibiotix-research-at-industry-conference-in-san-diego-186243.html
<![CDATA[RNS press release - Presentation of research ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171026070005_13409406/ Thu, 26 Oct 2017 07:00:05 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171026070005_13409406/ <![CDATA[News - Optibiotix ties with Spain's Galenicum to extend reach of microbiome-based cholesterol reducer ]]> http://www.proactiveinvestors.co.uk/companies/news/186076/optibiotix-ties-with-spain-s-galenicum-to-extend-reach-of-microbiome-based-cholesterol-reducer-186076.html Human microbiome specialist OptiBiotix Health PLC (LON:OPTI) has agreed for its cholesterol and blood pressure reducing LP-LDL strain to be sold in Spain, Chile, Peru and the Middle East in a three-year deal with Galenicum Special Ingredients.

The non-exclusive deal will see LP-LDL added to Galenicum's STOP&GO range of capsules, which are sold under the brand Cardiocare.

READ: Cholesterol drug failures spark big pharma interest in Optibiotix's microbiome-based alternative

 

Headquartered in Barcelona, Galenicum is one of Spain's leading pharmaceutical groups with an annual turnover of €100mln.

The company was awarded "Business of the Year" in 2013/2014 in the European Business Awards. 

OptiBiotix said the agreement will expand sales of LP-LDL into the Middle East and Latin America where heart disease accounts for half of deaths and often are the result of high blood pressure (hypertension).

"Product sales are difficult to estimate in these new territories and markets but are likely to be in the low to mid six figure in the near term and growing as Galenicum builds market presence," said the statement.  

READ: US launch of new microbiome products generates plenty of interest, says Optibiotix

Stephen O'Hara, Optibiotix’s chief executive, added Galenicum was chosen as a partner due to its leading position in the pharmaceutical industry, presence in new territories, and record of double digit sales growth.

“We see this agreement as another step in building multiple revenue streams with LP-LDL  as the 'Intel inside' different presentations and formulations developed with leading industry partners to access consumer and pharmaceutical markets around the world."

OptiBiotix has been a pioneer of products based around the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

Small changes to the gut flora can affect the way the human body processes food, which has led to a range of products being developed that are approaching the commercial stage.

O'Hara added that since June Optibiotix has signed six deals involving LP-LDL, which he described as a phenomenal rate of sign-ups.

Shares rose a touch to 70.55p. 

--adds detail, share price--

 

 

 

]]>
Tue, 24 Oct 2017 07:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/186076/optibiotix-ties-with-spain-s-galenicum-to-extend-reach-of-microbiome-based-cholesterol-reducer-186076.html
<![CDATA[RNS press release - LPLDL® supply agreement with Galenicum ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171024070002_13406237/ Tue, 24 Oct 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171024070002_13406237/ <![CDATA[News - Cholesterol drug failures spark big pharma interest in Optibiotix's microbiome-based alternative ]]> http://www.proactiveinvestors.co.uk/companies/news/185799/cholesterol-drug-failures-spark-big-pharma-interest-in-optibiotix-s-microbiome-based-alternative-185799.html Microbiome specialist Optibiotix PLC (LON:OPTI) has seen a marked increase in cholesterol lowering product LP-LDL from ‘big pharma’ after another high profile development failure.

Merck pulled the plug on its cholesterol lowering drug Anacetrapib last week after disappointing trial results.

Pfizer had already scrapped a similar protein inhibiting product, bococizumab in December, while Roche, Bristol-Myers Squibb and Eli Lilly have all suffered disappointments in this area.

Stephen O’Hara, Optibiotix’s chief executive, said the failures of these drugs had sparked interest in a possible combination with LP-LDL its own natural cholesterol reducing product.

The problems with these failings in high cost drug development is that it limits the therapeutic options, he told Proactive.

“This is increasing pharma’s interest in safe proven natural alternatives like LP-LDL to supplement and extent the patent life of existing drugs with combination therapies.“

Optibiotix had seen big pharma interest “build” over the past 3-4 months following Pfizer’s move and he expects this to grow as “The interface between food and pharmaceuticals narrows.”

A food additive, LP-LDL‘s efficacy is at a similar level to pharmaceutical products but with fewer side effects.

Any collaboration would likely take the form of a licensing/joint venture deal.

Anecdotally, LP-LDL is also showing good efficacy in reducing blood pressure as well as lowering cholesterol, said O’Hara.

One example, on the Optibiotix website, cites a person in their fifties who saw their blood pressure reduce more by using LP-LDL than through the ACE Inhibitor they had been prescribed. ACE Inhibitors are drugs designed to lower blood pressure by reducing angiotensin II in the body.

While this was only one person, O’Hara added that its own research had indicated a similar group effect on blood pressure and cholesterol across a much wider population (young, old, men and women,) and in much higher population numbers.

“It also shows the higher the blood pressure or cholesterol the greater the effect so the benefits are greatest in those most in need. “ 

A noticeable beneficial effect on hypertension (high blood pressure) would be a significant differentiator for LP-LDL, O’Hara said, and if possible it will try to find a partner to carry out further clinical studies.

OptiBiotix has been a pioneer of products based around the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

Small changes to the gut flora can affect the way the human body processes food and that had led to a range of products being developed by the company that are now approaching the commercial stage.

The strategy so far has been to find commercial rather than research partners.

A memorandum of understanding has already been signed with Bened to explore opportunities to combine LP-LDL with the Taiwanese firm’s PS128, a psycho-biotic that has shown encouraging results in reducing anxiety and depression in animal studies.

Industry leaders Tata Chemical and pro-biotics specialist Sacco have also all recently agreed deals for a variety of Optibiotix’s products.

Tata’s deal was for appetite suppressant Slimbiome. A new version of the flour-like weight loss additive was launched in the US at Las Vegas last month.

]]>
Wed, 18 Oct 2017 11:00:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/185799/cholesterol-drug-failures-spark-big-pharma-interest-in-optibiotix-s-microbiome-based-alternative-185799.html
<![CDATA[News - US launch of new microbiome products generates plenty of interest, says Optibiotix ]]> http://www.proactiveinvestors.co.uk/companies/news/185030/us-launch-of-new-microbiome-products-generates-plenty-of-interest-says-optibiotix-185030.html OptiBiotix Health PLC (LON:OPTI) has launched its SlimBiome and LP products in the US at the Supply Side West trade show.

Both products recently received FDA registration and the presentation at Supply Side West was the first in a number of steps to attract food, beverage, consumer healthcare and pharmaceutical partners for distribution and sale into the US market.

READ: Optibiotix Health lines up the targets for its “Precision microbiome engineering”

Cholesterol reducer LP was co-exhibited with Sacco, one of the largest suppliers of probiotic ingredients, while appetite suppressant SlimBiome was co-exhibited with specialty ingredients manufacturer, Cereal Ingredients. 

The event was attended by 16,500 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries with high interest from around the world, said the company.

Additionally, Optibiotix said that Sacco has appointed Dr Lucio Lepera as product manager for LP’s entry into the US probiotic market and extend it into the dairy market.

READ: OptiBiotix 'gaining real commercial traction' - CEO Stephen O'Hara

Cereal Ingredients, meanwhile, has incorporated SlimBiome into its range of cereal-based particulates and speciality ingredients that includes bakery products, breakfast cereals, crackers, toppings, products that extend it into the nutraceutical, health and wellbeing industry sectors. 

Stephen O'Hara, OptiBiotix’s chief executive, said in a statement: "We are extremely pleased with the very high level of interest from both national and multinational companies interested in our products and the opportunity to meet with senior US and Asian decision makers at Supply Side West. 

He added looking for partners was a low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products.

]]>
Wed, 04 Oct 2017 08:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/185030/us-launch-of-new-microbiome-products-generates-plenty-of-interest-says-optibiotix-185030.html
<![CDATA[RNS press release - Successful launch of products at Supply Side West ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171004070007_13385059/ Wed, 04 Oct 2017 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20171004070007_13385059/ <![CDATA[News - Optibiotix Health lines up the targets for its “Precision microbiome engineering” ]]> http://www.proactiveinvestors.co.uk/companies/news/184447/optibiotix-health-lines-up-the-targets-for-its-precision-microbiome-engineering-184447.html Stephen O’Hara, Optibiotix Health PLC's (LON:OPTI) chief executive, believes his company will have ‘many shots on goal’ in the coming years as it develops its range of products based around the human microbiome.

The company has scored once already with the recent float of SkinBioTherapeutics PLC (LON:STBX), a company that has grown in value from around £400,000 to £11mln and an AIM listing in little more than a year.

Now the plan is to repeat the formula with the group’s three other divisions.

Microbiome pioneer

OptiBiotix has been a pioneer of the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

Small changes to the gut flora can affect the way the human body processes food and that had led to a range of products being developed by the company that are now approaching the commercial stage.

O’Hara says it can use bacteria to build complex sugars that act like fibres, which allows it change the microbiome in a very targeted way.

“Precision microbiome engineering” is what O’Hara calls it and it’s a phrase he says the market is going to be hearing much more of in future.

Separate listings 

O’Hara sees potential for each of its weight loss, pro-biotics and sugars operations, and indeed Skinbiotherapeutics where it still has a 42% stake, to match Optibiotix’s current market value. 

The process of separating the three divisions along the lines of SkinBiotherapeutics has already started with Optibiotix also beefing up the commercial capability of each.

Eventually that may see further separate listings or even a Nasdaq listing for the whole group.

“We were a science company, now we are a commercial company with proven technologies and proven products in the market place.”

Products now the focus

Industry leaders Tata Chemical, pro-biotics specialist Sacco and Bened in Asia have all recently agreed deals for a variety of Optibiotix’s products.

Tata’s deal was for appetite suppressant Slimbiome. A  new version of the flour-like weight loss additive will be launched in the US at Las Vegas this week while a backlog of orders has built up from the earlier VitaFoods exhibition in Europe.

The upgrade makes its easier to mix, easier to dissolve and ensures better flavours opening up markets such as gym users who want a shake and bakeries that can fold it in for bread.

O'Hara says he had one order before the product had even gone on show at Vitafoods

Risk strategy pays off

When starting Optibiotix he knew working on the microbiome would be really exciting but to spread the risk, because it was so new, went for a number of different options.

“In three years in a new area of science, the microbiome, we’ve developed across four areas, developed 60 patents, twenty trademarks and are now starting to launch products.”

“We thought one or two might fail, but all have worked."

At 65.2p, Optibiotix is valued at £51.4mln.

]]>
Fri, 22 Sep 2017 11:41:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/184447/optibiotix-health-lines-up-the-targets-for-its-precision-microbiome-engineering-184447.html
<![CDATA[Media files - OptiBiotix 'gaining real commercial traction' - CEO Stephen O'Hara ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8105/optibiotix-gaining-real-commercial-traction-ceo-stephen-o-hara-8105.html Tue, 19 Sep 2017 15:36:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/8105/optibiotix-gaining-real-commercial-traction-ceo-stephen-o-hara-8105.html <![CDATA[News - Optibiotix Health to launch improved version of weight loss product Slimbiome ]]> http://www.proactiveinvestors.co.uk/companies/news/184189/optibiotix-health-to-launch-improved-version-of-weight-loss-product-slimbiome-184189.html OptiBiotix Health plc (LON:OPTI) is to launch an improved version of its hunger suppressant/weight loss product Slimbiome at a major US trade fair at the end of the month.

The new formulation is a single homogenous product, a development that reduces separation in transport and makes it available in places such as in-store bakeries where previously it might have been difficult to blend or remix.

Solubility has also been improved, making it taste and feel better in existing products such as 'GoFigure' shakes and bars.

Improved dispersion in water will help open new markets, said Stephen O’Hara, chief executive as it makes it ideal for gym users who want to mix it into a liquid shake

The new formula will also be cheaper to produce as there is less waste.

Optibiotix already has US product registration for Slimbiome, which is a patented combination of natural ingredients, and will launch the new version at the Supply Side West trade show where it will be exhibited with Cereal Ingredients Inc, a potential joint development partner.

READ: OptiBiotix technology gaining commercial traction; more to come says broker

Cereal Ingredients is considering incorporating SlimBiome into a range of cereal based particulates and ingredients aimed at the nutraceutical, health and wellbeing sectors. 

Other manufacturers are looking at SlimBiome's possible application into 'Health & Wellbeing' food and beverage products.  

READ: OptiBiotix to hook-up with Bened Biomedical to open new routes into south-east Asia for its cholesterol reduction products

Optibiotix is also launching its LPLDL cholesterol and blood pressure lowering product at Supply Side West, which takes place in Las Vegas on 27-28 September. 

O'Hara added: "We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners.

“As we build the range of applications, products and geographic scope of SlimBiome with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products.”

House broker finncap said the new formula was further evidence of the commercial progress the company is making, with the fact that talks with under way with other potential partners (to add to recent deals with Sacco and Tata Chemical) an encouraging development.

Shares rose 0.5% to 67.9p.

--Adds broker comment, detail and share price--

]]>
Tue, 19 Sep 2017 07:30:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/184189/optibiotix-health-to-launch-improved-version-of-weight-loss-product-slimbiome-184189.html
<![CDATA[RNS press release - Technical, regulatory & commercial update ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170919070003_13366966/ Tue, 19 Sep 2017 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170919070003_13366966/ <![CDATA[News - OptiBiotix technology gaining commercial traction; more to come says broker ]]> http://www.proactiveinvestors.co.uk/companies/news/183167/optibiotix-technology-gaining-commercial-traction-more-to-come-says-broker-183167.html OptiBiotix Health PLC (LON:OPTI) said its interim results charted a period of "significant” commercial  progress, including product launches and sales agreements.

Key among the deals inked was one with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.

It is one of a number of pro-biotic products developed by the life sciences company that tackle obesity, high cholesterol and diabetes.

Sacco deal inked

LPLDL is another of its innovations that is gaining market traction. OptiBiotix struck a profit-sharing deal with Italian firm Sacco to manufacture and supply cholesterol-reducing compound and the first sales of the product were made to HLH BioPharma Vertriebs·    

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.

Deals with Sacco and HLH, meanwhile, were expanded after the period-end, while in September the company signed a memorandum of understanding (MOU) with Bened Biomed that could open up markets in south-east Asia to the LPLDL strain. The MoU provides a 12-month period to explore opportunities relating to OptiBiotix's cholesterol and blood pressure reducing LPLDL strain and Bened’s PS128, a psycho-biotic that has shown encouraging results in reducing anxiety and depression in animal studies.

OptioBiotix said the agreement includes: the potential for Bened to commercialise OptiBiotix’s  LPLDL strain in Taiwan, Japan, Korea, and South East Asia; the potential for OptiBiotix to commercialise Bened’s PS128 strain in Europe and the USA; and the possibility of combining relevant assets to broaden the commercial offering and global reach

Positive financial performance

The financial performance of the company was positively impacted by the spin-off earlier this year of subsidiary Skinbiotherapeutics as a separate AIM-listed company valued at £4.5mln.

This resulted in a change in value of Opti’s investment in the business of £4.1mln. This adjustment led to the company posting a pre-tax profit of £3.2mln for the six months ended May.

CEO upbeat

Chief executive Stephen O’Hara was upbeat on what was achieved as well as the prospects for remainder of the financial year.

"OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base,” he said.

“This has stimulated industry interest from both national and multinational companies in selling our products in both consumer health and pharmaceutical markets around the world.

“The microbiome has been described by commentators as healthcare's 'most promising and lucrative frontier'.

“As OptiBiotix's microbiome modulating platforms generate products and multiple revenue streams from royalties and supply agreements, there is potential for a significant enhancement in the value of the company.”

Microbiome pioneer

OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

With this in mind, it is developing compounds to tackle obesity, high cholesterol and diabetes, as well as potential products for skin care.

Its LPLDL formulation comes from the bacterial species Lactobacillus plantarum.

Lactobacilli are common components of the human intestine and used by the food industry as probiotics.

Strong intellectual property

“[The] strong IP and broad portfolio is being shown to attract high calibre companies and, given the current rate of commercial deal signings, we anticipate current third-party interest to continue converting into licence deals, supply agreements and royalty revenues in the coming months,” said finnCap analyst Alex Pye in a note to clients.

After spinning off its SkinBio business as a separately listed entity earlier this year, the group is now focused on three development areas.

They are OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

Further spin-offs?

Having created value from the SkinBio spin-off, CEO O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

He said he hoped any listing would be planned sometime by the end of this year and the beginning of next, once each division has built up its IP, development programmes, and commercial partnerships.

The firm’s boss also said he plans to give some more of the value from the SkinBio float back to Opti shareholders in the future as well, in a way that is best for both firms.

Creating value

The aim, he said, is to further the commercialisation phase of the business, increasing revenues organically, but is also exploring the opportunity to make a strategic acquisition as well, which may be the only reason for the firm to raise any further cash, given its healthy balance sheet.

Certainly, Opti has provided shareholders with value thus far with the stock changing hands for 69p, compared with a flotation price in August 2014 of 8p a share.

If O’Hara and his team can deliver on his plans, that value could be very much enhanced.

]]>
Wed, 13 Sep 2017 12:07:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183167/optibiotix-technology-gaining-commercial-traction-more-to-come-says-broker-183167.html
<![CDATA[News - OptiBiotix to hook-up with Bened Biomedical to open new routes into south-east Asia for its cholesterol reduction products ]]> http://www.proactiveinvestors.co.uk/companies/news/183899/optibiotix-to-hook-up-with-bened-biomedical-to-open-new-routes-into-south-east-asia-for-its-cholesterol-reduction-products-183899.html OptioBiotix Health PLC (LON:OPTI) is planning to hook-up with Bened Biomedical of Taiwan to explore licensing and sales opportunities over the next 12 months.

The life sciences business focused on tackling obesity, high cholesterol and diabetes has signed a memorandum of understanding (MOU) with Bened.

The MoU provides a 12-month period to explore opportunities relating to OptiBiotix's cholesterol and blood pressure reducing LPLDL strain and Bened’s PS128, a psycho-biotic that has shown encouraging results in reducing anxiety and depression in animal studies. 

OptioBiotix said the agreement includes: the potential for Bened to commercialise OptiBiotix’s  LPLDL strain in Taiwan, Japan, Korea, and South East Asia; the potential for OptiBiotix to commercialise Bened’s PS128 strain in Europe and the USA; and the possibility of combining relevant assets to broaden the commercial offering and global reach

The Aim-listed firm said the partnership, should it come to fruition, would widen its probiotic portfolio into the area of psycho-biotics – where bacteria in the gut communicates with the brain (the “gut-brain axis”).

Referring to the “Microbiota-Gut-Brain Axis”, OptiBiotix said there is mounting evidence that suggests the microbiome helps shape neural development, brain biochemistry and behaviour.

New markets

The partnership would also open up commercial routes for the UK company into Asian markets, including Japan – the world's third largest dietary supplements market - with a total probiotic retail value of US$16.1bn, of which supplements account for US$700mln, according to Euromonitor International.

“We are pleased to announce this strategic partnership with Bened Biomedical and see a strong rationale for both companies to work together based on a complementary understanding of the science in different application areas of the microbiome," said Stephen O'Hara, chief executive officer of OptiBiotix.

“We are excited by recent advances in psycho-biotics which have the potential to address a range of mental and emotional health issues such as anxiety, depression, autism and Parkinson’s. We strongly believe Bened’s scientific and commercial capabilities in psychobiotics creates potential for OptiBiotix to bring new products to new markets and extend both our product offering and global reach in the microbiome field to bring better science and better health to all,” he added.

READ: OptiBiotix set to launch its cholesterol-reducing strain in US next month

Frankie Cheng, chief executive of Bened Biomedical, was similarly effusive about the possibilities of the partnership.

"OptiBiotix operates in a very exciting and progressive area that has the potential to bring real health benefits,” he said.

“It has exciting products with strong science and clinical studies which we believe can be commercialised successfully through our distribution capability. We see mutual benefit in OptiBiotix’s commercial advances in Europe and US as a way to bring our PS128 product to a wider audience,” he added.

Summing things up, OptiBiotix's house broker, finnCap, said: “Geographically, OPTI will benefit by potentially going on to commercialise LP-LDL into Taiwan, Japan, Korea and SE Asia, whilst Bened could benefit through OPTI commercialising its PS128 strain in Europe and the US.”

“The widening of OPTI's probiotic portfolio into psychobiotics allows for wider potential markets opportunities going forward and is positive, given that Bened is established in this area as a market leader,” said analysts Alex Pye and Mark Brewer.

Bened Biomedical is a Taiwanese probiotic company whose patented product PS128 already has sales (including online) and is sold internationally in over ten countries, finnCap noted.

Earlier animal studies for PS128 have shown encouraging results in reducing anxiety and depression, it added.

Shares in OptiBiotix rose 0.6% to 69.89p in a falling market on the news.   

READ: OptiBiotix inks sweet manufacturing deal with Indian food ingredients giant Tata Chemicals ]]>
Wed, 13 Sep 2017 08:52:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183899/optibiotix-to-hook-up-with-bened-biomedical-to-open-new-routes-into-south-east-asia-for-its-cholesterol-reduction-products-183899.html
<![CDATA[RNS press release - Strategic partnership with Bened Biomedical ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170913070003_13360669/ Wed, 13 Sep 2017 07:00:03 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170913070003_13360669/ <![CDATA[RNS press release - Holding(s) in Company ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170911120001_13358413/ Mon, 11 Sep 2017 12:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170911120001_13358413/ <![CDATA[RNS press release - Invited to present at Expoquimia in Barcelona ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170907070007_13354508/ Thu, 07 Sep 2017 07:00:07 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170907070007_13354508/ <![CDATA[RNS press release - Investor evening ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170906093001_13353332/ Wed, 06 Sep 2017 09:30:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170906093001_13353332/ <![CDATA[Media files - Optibiotix signs 'very good' manufacturing deal with Tata Chemicals ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/8033/optibiotix-signs-very-good-manufacturing-deal-with-tata-chemicals-8033.html Tue, 05 Sep 2017 14:17:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/8033/optibiotix-signs-very-good-manufacturing-deal-with-tata-chemicals-8033.html <![CDATA[News - OptiBiotix inks sweet manufacturing deal with Indian food ingredients giant Tata Chemicals ]]> http://www.proactiveinvestors.co.uk/companies/news/183431/optibiotix-inks-sweet-manufacturing-deal-with-indian-food-ingredients-giant-tata-chemicals-183431.html Life sciences group OptiBiotix Health plc (LON:OPTI) has signed a manufacturing agreement with India-listed food ingredients giant Tata Chemicals.

It is an expansion of a deal the two inked last December and gives Tata, part of the Tata Group, the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain.

WATCH: Opti boss on 'very good' deal with Tata READ: Opti partners up with multinational as it targets Asian weight loss markets

The sugar – galacto-oligosaccharide – will be used in various food and over-the-counter products, subject to its successful development at pilot development.

When digested they stimulate the growth of ‘good’ gut bacteria, which Opti has showed can lead to improved health and help to tackle ‘chronic lifestyle diseases’ such as diabetes and obesity.

This agreement with Tata focuses on the Asian markets, particularly India, but Opti is in talks with other companies about manufacturing the cholesterol and blood pressure-lowering strain in other markets such as the US.

READ: OptiBiotix set to launch its cholesterol-reducing strain in US soon

“We believe the combination of OptiBiotix's ability to develop ingredients which can modify an individual's microbiome, and Tata's research and manufacturing expertise, international reputation, and global reach, places both companies at the forefront of global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“This agreement takes both companies further down the path of translating the science of the microbiome field into products which will improve the health and wellbeing of people around the world.”

City broker praises 'interesting' deal

"The announcement is interesting in that TATA recently launched its own GOS related first general health product and is a major supplier of pharmaceutical industries both within India and globally," said finnCap analyst Lorne Daniel.

"Whilst only in the earliest stages of development, we are encouraged by this announcement and continue to recognise the commercial milestones that OPTI's management are steadily and reliably delivering upon."

Shares rose 5.35%, or 3.8p, to 74.8p.

--Updates for broker comment, video link and share price--

]]>
Tue, 05 Sep 2017 07:45:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183431/optibiotix-inks-sweet-manufacturing-deal-with-indian-food-ingredients-giant-tata-chemicals-183431.html
<![CDATA[RNS press release - Manufacturing Agreement with Tata Chemicals ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170905070001_13351538/ Tue, 05 Sep 2017 07:00:01 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170905070001_13351538/ <![CDATA[RNS press release - Exercise of Options and Issue of Equity ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170901144145_13349451/ Fri, 01 Sep 2017 14:41:45 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170901144145_13349451/ <![CDATA[News - OptiBiotix interims chart a period of significant commercial progress ]]> http://www.proactiveinvestors.co.uk/companies/news/183145/optibiotix-interims-chart-a-period-of-significant-commercial-progress-183145.html OptiBiotix Health PLC (LON:OPTI) said its interim results charted a period of "significant” commercial  progress, including product launches and sales agreements.

The life sciences company is developing pro-biotic compounds that tackle obesity, high cholesterol and diabetes.

READ:OptiBiotix set to launch its cholesterol-reducing strain in US next month

Key among the deals inked was one with Tata Chemicals to develop weight management products containing its SlimBiome additive for the Indian market.

Sacco deal inked

It also has a profit-sharing deal with Italian firm Sacco to manufacture and supply OptiBiotix's cholesterol-reducing strain, LPLDL. The first sales of this particular product were made to HLH BioPharma Vertriebs.    

At the same time it has a non-exclusive agreement with Nutrilinea for the production and commercialisation of products containing the LPLDL in Europe.

Deals with Sacco and HLH, meanwhile, have been expanded since the period-end.

WATCH: Optibiotix broadens tie-up with Sacco to cover US and rest of the world

The financial performance of the company was positively impacted by the spin-off earlier this year of subsidiary Skinbiotherapeutics as a separate AIM-listed company valued at £4.5mln.

This resulted in a change in value of Opti’s investment in the business of £4.1mln. This adjustment led to the company posting a pre-tax profit of £3.2mln for the six months ended May.

CEO upbeat

Chief executive Stephen O’Hara was upbeat on what was achieved as well as the prospects for remainder of the financial year.

"OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base,” he said in a statement.

“This has stimulated industry interest from both national and multinational companies in selling our products in both consumer health and pharmaceutical markets around the world.

“The microbiome has been described by commentators as healthcare's 'most promising and lucrative frontier'.

“As OptiBiotix's microbiome modulating platforms generate products and multiple revenue streams from royalties and supply agreements, there is potential for a significant enhancement in the value of the company.”

]]>
Wed, 30 Aug 2017 07:24:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/183145/optibiotix-interims-chart-a-period-of-significant-commercial-progress-183145.html
<![CDATA[RNS press release - Half-year Report ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170830070002_13344905/ Wed, 30 Aug 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170830070002_13344905/ <![CDATA[News - OptiBiotix set to launch its cholesterol-reducing strain in US next month ]]> http://www.proactiveinvestors.co.uk/companies/news/182913/optibiotix-set-to-launch-its-cholesterol-reducing-strain-in-us-next-month-182913.html OptiBiotix Health PLC (LON:OPTI) saw its shares gain today on news it is set to launch its LPLDL cholesterol and blood pressure lowering strain in the United States next month.

In late afternoon trade, Optibiotix shares were ahead 5%, or 3.5p at 73.0p.

WATCH Milestone for Optibiotix with first sales in Germany of LPLDL capsules

In a note to clients, analysts at finnCap said: “The US is one of the largest and fastest-growing probiotic markets in the world, with expected sales of $3.3bn in 2021.

“Following on from the recent expansion of OPTI's manufacturing and supply agreement with Sacco, this is yet another example of the commercial development and industry awareness of the LP-LDL brand.”

News of the Stateside launch comes just days after Opti announced a global manufacturing and supply agreement with Italian food company Sacco.

The two – Opti and Sacco – will co-exhibit at the Supply Side West trade show in Las Vegas at the end of September, where they will present various products that contain the LPLDL strain.

Significant progress in raising industry awareness 

Among the products they’ll be showing off will be CholBiome and CardioBiome – both of which contain the LPLDL strain – as well as some new concepts.

“OptiBiotix has made significant progress in raising industry awareness of its LPLDL strain,” said chief executive Stephen O’Hara.

“This has created a high level of interest in commercialising products containing LPLDL as a component in higher value branded products in markets globally.”

“Exhibiting at Supply Side West creates the opportunity to communicate with high-end decision makers in the US market with the potential to generate revenues for different formulations and presentations across numerous applications at multiple points in the value chain with US and international partners.”

Latest step in building global profile of LPLDL

OptiBiotix has previously taken various steps to build the profile of LPLDL in Europe, including a non-exclusive licence agreement with Italy-based food supplements provider, Nutrilinea.

It said that the upcoming launch in Las Vegas would be the “first of a number of steps taken” to get partners from the US on board.

The US probiotic market will be key for OptiBiotix going forward, given its size and the rate at which it is growing. Supplements alone generated more than US$2bn in sales last year, while experts reckon that will grow to US$3.3bn by 2021.

With Europe and the US almost ticked off the list, the AIM-quoted group said it is in discussions with possible corporate partners for the manufacture and distribution of products containing LPLDL in the Asian and other international markets.

 -- Adds share price, analyst comment --

]]>
Thu, 24 Aug 2017 07:46:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/182913/optibiotix-set-to-launch-its-cholesterol-reducing-strain-in-us-next-month-182913.html
<![CDATA[RNS press release - US product launch of LPLDL® at trade show ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170824070002_13340075/ Thu, 24 Aug 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170824070002_13340075/ <![CDATA[Media files - Optibiotix broadens tie-up with Sacco to cover US and rest of the world ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7974/optibiotix-broadens-tie-up-with-sacco-to-cover-us-and-rest-of-the-world-7974.html Tue, 22 Aug 2017 12:20:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7974/optibiotix-broadens-tie-up-with-sacco-to-cover-us-and-rest-of-the-world-7974.html <![CDATA[News - OptiBiotix Health expands its supply agreement with Italian food company ]]> http://www.proactiveinvestors.co.uk/companies/news/182783/optibiotix-health-expands-its-supply-agreement-with-italian-food-company-182783.html OptiBiotix Health PLC (LON:OPTI) has announced an expansion of a key manufacturing and supply agreement.

It is broadening its European tie-up with Italian food company Sacco, signed in March, to cover the US and rest of the world.

WATCH: Optibiotix broadens tie-up with Sacco to cover US and rest of the world

The deal gives Sacco the exclusive right to manufacture and supply OptiBiotix's cholesterol and blood pressure reducing LPLDL bacterial strains in the new territories.

Sacco will receive 50% of all profits and the two have agreed a guaranteed cost of manufacture and minimum sales price per kilogramme to secure against discounting.

READ: Milestone for Optibiotix with first sales in Germany of LPLDL capsules Big market

The food additive can now be sold in America, the world’s largest probiotic market with annual sales of US$7.1bn. The new supply agreement will also see an extension of the LPLDL technology into dairy applications, which is a US$35.5bn market.

As important are the synergies from transaction with the economies of greater scale kicking in. It will also ensure long-term security of supply with Sacco's ability to produce at different locations from multiple facilities.

"This new agreement significantly extends the scale of the commercial opportunity open to LPLDL to new application areas and territories, and reflects growing confidence from both companies in LPLDL's market potential,” said chief executive Stephen O’Hara.

READ: FinnCap expects more deals to follow OptiBiotix's latest distribution deal

“We chose Sacco as we have been impressed by their ability to introduce LPLDL to a global network of distributors and believe extending our partnership with them provides the best opportunity of quickly building revenues and developing LPLDL into a global brand.

“In addition, the ability to supply competitively priced ingredients from a single manufacturer across world markets simplifies the supply chain and contract negotiations with corporate partners."

]]>
Tue, 22 Aug 2017 07:26:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/182783/optibiotix-health-expands-its-supply-agreement-with-italian-food-company-182783.html
<![CDATA[RNS press release - Global manufacturing & supply agreement with Sacco ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170822070002_13337186/ Tue, 22 Aug 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170822070002_13337186/ <![CDATA[RNS press release - Total Voting Rights ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170731162730_13313763/ Mon, 31 Jul 2017 16:27:30 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170731162730_13313763/ <![CDATA[Media files - Milestone for Optibiotix with first sales in Germany of LPLDL capsules ]]> http://www.proactiveinvestors.co.uk/companies/stocktube/7840/milestone-for-optibiotix-with-first-sales-in-germany-of-lpldl-capsules-7840.html Wed, 26 Jul 2017 12:39:00 +0100 http://www.proactiveinvestors.co.uk/companies/stocktube/7840/milestone-for-optibiotix-with-first-sales-in-germany-of-lpldl-capsules-7840.html <![CDATA[News - OptiBiotix passes major commercial milestone as cholesterol capsules go on sale in Germany ]]> http://www.proactiveinvestors.co.uk/companies/news/181454/optibiotix-passes-major-commercial-milestone-as-cholesterol-capsules-go-on-sale-in-germany-181454.html OptiBiotix Health PLC (LON:OPTI) has reached a significant milestone following the first sales in Germany of a new range of cholesterol-lowering capsules containing its breakthrough LP-LDL technology.

It follows the successful registration by partner HLH Biopharma (HLH) of the product, known as Lactobact, which uses naturally occurring strains of bacteria.

“We hope this will be the first of many product launches of multiple formulations and presentations of LP-LDL as the active component in a wide range of pharmaceutical and consumer products around the world,” said chief executive Stephen O’Hara.

WATCH: Milestone for Optiobiotix with first sales in Germany of LPLDL capsules

“HLH have an international reputation for providing high quality and scientifically validated products and are one of Europe's leading suppliers of probiotics to the pharmacy market. 

“Establishing early sales of LP-LDL to pharmacies with HLH helps substantiate the credibility in the science behind LP-LDL to build the brand and acceptance in the larger consumer healthcare markets."

Pioneer

OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin.

It has found, for instance, small changes to the gut flora can affect the way the human body processes food.

With this in mind, it is developing compounds to tackle obesity, high cholesterol and diabetes, as well as potential products for skin care.

Its LP-LDL formulation comes from the bacterial species Lactobacillus plantarum.

Lactobacilli are common components of the human intestine and used by the food industry as probiotics.

Unique line selected

LP-LDL is unique in that it was selected using OptiBiotix's Optiscreen platform from a collection of over 4,000 candidates for its “outstanding capacity” to hydrolyse bile salts.

This activity is crucial for both bacterial survival in the gut and its use to prevent and manage a number of health conditions such as high cholesterol, high blood pressure, glucose and energy regulation, vitamin metabolism, and liver function.

This creates the potential to use LP-LDL as the technology core of multiple products using the model pioneered by chipmaker Intel.

Broker expects more deals

The broker finnCap said revenues from Germany will be in the “low to mid six figures”.

Analyst Alex Pye expects further deals. “Management continues to deliver on key commercial milestones laid out at the time of our initiation,” he said.

“We expect OptiBiotix to continue to announce further supply agreements in the coming months with national pharmacies and large global consumer health partners.”

After spinning off its SkinBio business as a separately listed entity earlier this year, the group is now focused on three development areas.

They are OptiScreen, which is developing gut bacteria to help in lowering cholesterol; OptiBiotics which is developing SweetBiotix, its natural sweet fibre to help with diabetes control; and Slimbiome, its weight management product.

The firm already has commercial partners in place for all its platforms with global brands.

At the end of 2016, Opti partnered with Indian giant Tata to develop various weight management foods and products that contain its SlimBiome technology.

In March 2016, OptioBiotix also signed a deal with Sacco, one of Europe’s leading probiotic manufacturers and raw ingredients suppliers to manufacture and supply OptiBiotix's cholesterol reducing strain, LP-LDL, in Europe.

To give an idea of the size of the markets Opti is working in, finnCap estimates the functional (diet) foods market is worth £154bn annually.

Further action

Having created value from the SkinBio spin-off, O’Hara recently told Proactive Investors that his target is to build each of the three divisions into separate legal entities and possibly list each separately on London’s AIM market.

O’Hara said he hoped any listing would be planned sometime by the end of this year and the beginning of next, once each division has built up its IP, development programmes, and commercial partnerships.

The firm’s boss also said he plans to give some more of the value from the SkinBio float back to Opti shareholders in the future as well, in a way that is best for both firms.

Overall, O’Hara’s aim is to further the commercialisation phase of the business, increasing revenues organically, but is also exploring the opportunity to make a strategic acquisition as well, which may be the only reason for the firm to raise any further cash, given its healthy balance sheet.

Certainly, Opti has provided shareholders with value thus far with the stock changing hands for 66p, compared with a flotation price in August 2014 of 8p a share.

If O’Hara and his team can deliver on his plans, that value could be very much enhanced.

]]>
Wed, 26 Jul 2017 07:27:00 +0100 http://www.proactiveinvestors.co.uk/companies/news/181454/optibiotix-passes-major-commercial-milestone-as-cholesterol-capsules-go-on-sale-in-germany-181454.html
<![CDATA[RNS press release - Market launch for LPLDL® capsules in Germany ]]> http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170726070002_13307333/ Wed, 26 Jul 2017 07:00:02 +0100 http://www.proactiveinvestors.co.uk/companies/rns/10651/LSE20170726070002_13307333/